Furthermore, canagliflozin (Cana), a clinical-approved drug for type 2 diabetes, mimics glucose starvation and inhibits the growth of ACSL4-low xenograft tumors. This evidence concerns the gene ACSL4 and type 2 diabetes mellitus.